CN1616654A - Inactivating and purifying method for SARS virus and method for preparing said inactivated virus vaccine and said vaccine - Google Patents
Inactivating and purifying method for SARS virus and method for preparing said inactivated virus vaccine and said vaccine Download PDFInfo
- Publication number
- CN1616654A CN1616654A CN 200310114341 CN200310114341A CN1616654A CN 1616654 A CN1616654 A CN 1616654A CN 200310114341 CN200310114341 CN 200310114341 CN 200310114341 A CN200310114341 A CN 200310114341A CN 1616654 A CN1616654 A CN 1616654A
- Authority
- CN
- China
- Prior art keywords
- deactivation
- sars virus
- viral
- virus
- liquid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000315672 SARS coronavirus Species 0.000 title claims abstract description 83
- 241000700605 Viruses Species 0.000 title claims abstract description 52
- 229960005486 vaccine Drugs 0.000 title claims abstract description 42
- 238000000034 method Methods 0.000 title claims abstract description 38
- 230000000415 inactivating effect Effects 0.000 title abstract description 7
- 230000009849 deactivation Effects 0.000 claims description 88
- 239000007788 liquid Substances 0.000 claims description 62
- 230000003612 virological effect Effects 0.000 claims description 57
- 230000002779 inactivation Effects 0.000 claims description 46
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 34
- 238000000108 ultra-filtration Methods 0.000 claims description 26
- 239000000243 solution Substances 0.000 claims description 20
- 101000674278 Homo sapiens Serine-tRNA ligase, cytoplasmic Proteins 0.000 claims description 19
- 101000674040 Homo sapiens Serine-tRNA ligase, mitochondrial Proteins 0.000 claims description 19
- 102100040516 Serine-tRNA ligase, cytoplasmic Human genes 0.000 claims description 19
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 claims description 19
- 229960000380 propiolactone Drugs 0.000 claims description 19
- 239000000427 antigen Substances 0.000 claims description 12
- 102000036639 antigens Human genes 0.000 claims description 12
- 108091007433 antigens Proteins 0.000 claims description 12
- 230000000937 inactivator Effects 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 12
- 238000000746 purification Methods 0.000 claims description 12
- 229940031551 inactivated vaccine Drugs 0.000 claims description 11
- 238000004587 chromatography analysis Methods 0.000 claims description 10
- 238000005352 clarification Methods 0.000 claims description 10
- 238000004440 column chromatography Methods 0.000 claims description 10
- 101710154606 Hemagglutinin Proteins 0.000 claims description 9
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims description 9
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims description 9
- 101710176177 Protein A56 Proteins 0.000 claims description 9
- 238000000502 dialysis Methods 0.000 claims description 9
- 239000000185 hemagglutinin Substances 0.000 claims description 9
- 238000005325 percolation Methods 0.000 claims description 9
- 210000003501 vero cell Anatomy 0.000 claims description 9
- 229920002684 Sepharose Polymers 0.000 claims description 8
- 239000002671 adjuvant Substances 0.000 claims description 8
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 108010034546 Serratia marcescens nuclease Proteins 0.000 claims description 7
- 238000002679 ablation Methods 0.000 claims description 7
- 229910021502 aluminium hydroxide Inorganic materials 0.000 claims description 7
- 230000029087 digestion Effects 0.000 claims description 7
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 230000001186 cumulative effect Effects 0.000 claims description 6
- 230000001954 sterilising effect Effects 0.000 claims description 6
- 238000004659 sterilization and disinfection Methods 0.000 claims description 6
- 206010022000 influenza Diseases 0.000 claims description 5
- 101710163270 Nuclease Proteins 0.000 claims description 4
- 241000712461 unidentified influenza virus Species 0.000 claims description 4
- GUTLYIVDDKVIGB-OUBTZVSYSA-N Cobalt-60 Chemical compound [60Co] GUTLYIVDDKVIGB-OUBTZVSYSA-N 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 230000000694 effects Effects 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 230000003067 hemagglutinative effect Effects 0.000 claims description 3
- 229960003971 influenza vaccine Drugs 0.000 claims description 3
- 230000002277 temperature effect Effects 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 239000008215 water for injection Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000010129 solution processing Methods 0.000 claims 1
- 229940124680 SARS vaccine Drugs 0.000 abstract description 2
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 10
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 238000011081 inoculation Methods 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 230000003472 neutralizing effect Effects 0.000 description 6
- 238000001514 detection method Methods 0.000 description 5
- 230000000890 antigenic effect Effects 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 238000006386 neutralization reaction Methods 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 241000711573 Coronaviridae Species 0.000 description 1
- 229940124872 Hepatitis B virus vaccine Drugs 0.000 description 1
- 241000709721 Hepatovirus A Species 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000012407 engineering method Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 229940041323 measles vaccine Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000002594 sorbent Substances 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
Images
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The present invention SARS virus inactivating method, the inactivated virus purifying method, the inactivated SARS vaccine preparing process, and the vaccine containing the said inactivated virus.
Description
Invention field
The present invention relates to a kind of ablation method of SARS virus, the purification process of described inactivation of viruses, the preparation technology of SARS inactivated vaccine, and the vaccine that contains described inactivation of viruses.
Background of invention
For preventing that effectively severe acute respiratory syndrome (Severe Acute RespiratorySyndrome is designated hereinafter simply as SARS) from China and even mondial spreading, pressing for the SARS virus vaccine that can effectively prevent to cause described illness at present.
With regard to vaccine kind commonly used, mainly can be divided into employing and cause immunoreactive genetically engineered type vaccine, as the genetically engineered Hepatitis B virus vaccine by specific virus surface antigen or its fragment that gene engineering method obtains; The attenuation type living vaccine that adopts virus to prepare behind attenuation is as Measles Vaccine,Live; And the deactivation type vaccine for preparing after by effective deactivation by the live body virus strain, as the hepatitis A virus inactivated vaccine.
In order to obtain can be used for clinical SARS virus vaccine at short notice, the inventor utilizes the SARS virus strain isolated available from clinical SARS patient, cultivate the SARS virus liquid that obtains high density through large-scale industrialization, successfully explore the ablation method of the described SARS virus of effective deactivation and the purification process of described inactivation of viruses, and successfully develop the vaccine that contains described inactivation of viruses thus.
Summary of the invention
One aspect of the present invention relates to a kind of ablation method of SARS virus.In SARS virus ablation method of the present invention, select for use formalin solution or beta-propiolactone as inactivator, can effectively realize the SARS virus deactivation, especially the deactivation of the SARS virus of heavy industrialization cultivation.Compare with traditional inactivation of virus mode, the method for the invention effectively deactivation of SARS virus has kept the antigenicity of described inactivation of viruses simultaneously to the level that meets production of vaccine.
In a specific embodiments of the present invention, select for use with viral sample cumulative volume ratio be 1: 1000-1: the SARS virus sample that 4000 formalin solution, 37 ℃ of processing are cultivated through heavy industrialization 2.9-12.5 hour, deactivation of SARS virus.In another specific embodiments of the present invention, select for use with viral sample cumulative volume ratio be 1: 4000-1: 8000 beta-propiolactone, at 2-8 ℃ of following deactivation of SARS virus 16-24 hour.
In the present invention can also be in the cell factory of scale preparation SARS virus the original position inactivation of viruses.In a specific embodiments of the present invention, with the inactivator for preparing (for example, formalin solution with volume ratio dilution in 1: 100) fills in the cell factory for the treatment of deactivation of SARS virus through the adding of closed pipeline system, formalin final concentration 1: 1000-4000, mixing, under agitation, gather in the crops after 2.9-12.5 hour through 37 ℃ of original position deactivations.
In another specific embodiments of the present invention, optional, also comprise overtime deactivation to gained SARS virus sample.Concrete, be inactivator with formalin, to being harvested from the SARS virus sample in the fixed container,, be preferably the overtime deactivation of 3 times (the deactivation condition is with deactivations first) of inactivation time first again through certain hour through deactivation first;
In another specific embodiments of the present invention, optional, also comprise secondary deactivation to gained SARS virus sample.Particularly, with beta-propiolactone solution is inactivator, with with viral sample cumulative volume ratio be that 1: 6000～1: 8000 amount adds in the SARS virus sample of aforementioned processing, deactivation is spent the night after (16-24hr), add again with viral sample cumulative volume ratio be that the amount of 1: 4000～1: 6000 (be twice add beta-propiolactone working concentration sum) is carried out the secondary deactivation, the condition of deactivation for the second time is at 2-8 ℃ of following deactivation of SARS virus 16-24 hour, room temperature effect 2 days or 37 ℃ of water-bath effects 2 hours are with the thorough deactivation of SARS virus.
After the method for the invention was implemented inactivation of virus, checking adopted the conventional sense method to detect for inactivating efficacy, for example, gained inactivation of virus liquid sample can be gone up 3 generations of blind passage at sensitive cells (as Vero-E6 or Vero cell), verified its inactivating efficacy.
Another aspect of the present invention relates to a kind of purification process of described deactivation of SARS virus.In the purifying process of SARS inactivation of viruses of the present invention, adopt steps such as for example centrifugal, ultrafiltration, combination chromatography, can effectively obtain highly purified deactivation of SARS virus, be used for the preparation of described deactivation of SARS virus vaccine.
In a specific embodiments of the present invention, adopted the technical scheme purifying inactivation of viruses that comprises viral clarification, ultrafiltration and concentration and column chromatography, gained viral purification liquid can be used for production of vaccine, can be used for the antigenic preparation of diagnostic reagent reference simultaneously.
In the method for viral purification of the present invention, can select at least a above-mentioned steps, or its arbitrary combination, to realize that final purifying inactivation of viruses is to the antigenic purpose that can be used in inactivated vaccine production and the preparation SARS detection reagent.
In another specific embodiments of the present invention, 1) inactivation of virus liquid is carried out centrifugal clarification, concrete with 2000～4000g centrifugal force 2-8 ℃ centrifugal 10～35 minutes, suct clearly, be viral clear liquor; 2) ultrafiltration and concentration: viral clear liquor is carried out ultrafiltration and concentration more than 10 times with the film bag of 100-500kd (molecular weight cut-off), equal-volume dialysis 3-7 time, dialyzate obtains viral ultrafiltrated with 0.01MPBS (pH7.0～7.6); And 3) column chromatography: viral ultrafiltrated is carried out chromatography with Sepharose four fast flow, and elutriant 0.01M PBS collects the first percolation peak and is viral consummate liquid.
In another specific embodiments of the present invention, 1) inactivation of virus liquid is carried out centrifugal clarification, concrete with 2000～4000g centrifugal force 2-8 ℃ centrifugal 10～35 minutes, suct clearly, be viral clear liquor; 2) ultrafiltration and concentration: viral clear liquor is carried out ultrafiltration and concentration more than 10 times with the film bag of 100-500kd (molecular weight cut-off), equal-volume dialysis 3-7 time, dialyzate obtains viral ultrafiltrated with 0.01MPBS (pH7.0～7.6); 3) to step 2) to add final concentration in the purified inactivation of viruses liquid of gained be the nuclease of 10-100 unit, is preferably Benzonase; Vero cell residue DNA in the digestion system; 4) ultrafiltration once more; With 5) column chromatography: viral ultrafiltrated is carried out chromatography with Sepharose four fast flow, and elutriant 0.01M PBS collects the first percolation peak and is viral consummate liquid.
In another specific embodiments of the present invention, 1) inactivation of virus liquid is carried out centrifugal clarification, concrete with 2000～4000g centrifugal force 2-8 ℃ centrifugal 10～35 minutes, suct clearly, be viral clear liquor; 2) ultrafiltration and concentration: viral clear liquor is carried out ultrafiltration and concentration more than 10 times with the film bag of 100-500kd (molecular weight cut-off), equal-volume dialysis 3-7 time, dialyzate obtains viral ultrafiltrated with 0.01MPBS (pH7.0～7.6); 3) column chromatography: viral ultrafiltrated is carried out chromatography with Sepharosefour fast flow, and elutriant 0.01M PBS collects the first percolation peak; 4) adding final concentration in the purified inactivation of viruses liquid of collecting in step 3) is the nuclease of 10-100 unit, is preferably Benzonase; Vero cell residue DNA in the digestion system; With 5) ultrafiltration once more, obtain viral consummate liquid.
The DNA enzyme of the Vero cell residue DNA that can effectively degrade that employed in the present invention DNA enzyme can be known in the art, preferred, described dna cleavage enzyme is Benzonase (Merck ﹠ Co., Inc.)
Another aspect of the present invention relates to a kind of deactivation of SARS virus vaccine, wherein contains the deactivation of SARS virus of immune significant quantity, and pharmaceutically acceptable carrier, and is optional, also contains the adjuvant of appropriate amount.In the present invention, described immune significant quantity is meant and can effectively produces immunoreactive amount after inoculation.Those skilled in the art can know how to select suitable inoculum size according to the approach of vaccine inoculation.In being suitable for vaccine of the present invention, the content of inactivation of viruses is 1-1000ug/ml in the described vaccine, is preferably 20-500ug/ml, is preferably 40-100ug/ml especially.
Can not use adjuvant in the vaccine of the present invention, perhaps use adjuvant commonly used in the vaccine production field to include but not limited to aluminum hydroxide adjuvant or influenza virus hemagglutinin.
The invention still further relates to a kind of method for preparing the deactivation of SARS virus vaccine.Concrete, will further pass through following processing through the viral purification liquid that is obtained behind the aforesaid method purifying:
1) with the consummate liquid of virus with being selected from 0.2 μ m filter or irradiance method degerming, obtain vaccinogen liquid;
2) vaccinogen liquid is diluted to total protein 10-50 mcg/ml, is packed as inactivated vaccine.
In the SARS virus vaccine production method of the present invention, filtration sterilization described in the step 1) is preferably adopts 0.2 μ m filter degerming, and irradiation sterilization preferably adopts the cobalt 60 of 4-10 kilogray (kGy) dosage to shine samples 60 minutes.
In the method for preparing vaccine of the present invention, step 2) can adopt water for injection dilution vaccinogen liquid in, can also adopt that to contain aluminium hydroxide concentration be 0.7-1.2mol/L, 0.01MPBS, pH6.8-7.2, aluminium hydroxide diluted vaccinogen liquid, vaccinogen liquid is diluted to total protein 10-50 mcg/ml or 10-100SU/ milliliter SARS antigen (SARS antigen unit represents that with SU 1SU is meant and can makes mouse produce 64 antigen amounts that neutralizing antibody unit is required) the most at last.Perhaps adopt the influenza vaccines stoste that contains influenza hemagglutinin that SARS vaccinogen liquid proportioning is imitated dosage SARS antigen, H as mentioned above to containing
1N
1, H
3N
2, the Type B influenza virus hemagglutinin is respectively greater than 12 micrograms.
In deactivation of SARS virus vaccine of the present invention, can comprise at least a strain that is selected from following coronavirus genus SARS virus of deactivation: Sino1, Sino2, Sino3, Sino4, and Sino5.Described virus stain is respectively at being deposited in the common micro-organisms center (CGMCC of China Committee for Culture Collection of Microorganisms of international depositary institution on June 27th, 2003, No. 13, one in Zhong Guan-cun, Haidian District, BeiJing, China city north), preserving number is respectively 0962,0963,0964,0965 and 0966.
The invention still further relates to the prevention Mammals especially the people avoid the method that SARS virus infects, comprise vaccine of the present invention to the individual immunoprophylaxis significant quantity of needs.Preferably, route of inoculation include but not limited to subcutaneous, nose interior, oral, intracutaneous, intramuscular or parenteral route.
Description of drawings
Fig. 1. select different formalin solution concentration to carry out the influence of deactivation to the SARS virus infection titer.
Fig. 2. select of the influence of different beta-propiolactone strength of solution to the SARS virus infection titer.
Embodiment
In the present invention, adopt the inactivator that is selected from formalin solution and beta-propiolactone, the sample that contains SARS virus is carried out deactivation.
1) formalin solution deactivation
In pending SARS virus sample, add the formalin solution that dilutes through 1: 100 (volume ratio) with equal-volume respectively, under 37 ℃, be respectively the formalin solution treatment S ARS virus liquid of 1: 1000,1: 2000,1: 4000 (volume ratio) dilution, obtain SARS virus and calculate that inactivation time was respectively 2.9 hours, 6.0 hours and 12.5 hours with working concentration.The result sees table 1 deactivation kinetic curve for details referring to Fig. 1.
The table 1 different concns formalin solution deactivation of SARS virus time
Calculate inactivation time before the deactivation
The formalin slope
CCID50/ml??????????????????(hr)
1∶1000???????6.7??????????-2.4???????????2.9
1∶2000???????6.7??????????-1.13??????????6.0
1∶4000???????6.7??????????-0.53??????????12.5
2) beta-propiolactone solution deactivation
In pending SARS virus sample, add the beta-propiolactone solution that dilutes through 1: 10 (volume ratio) with equal-volume respectively, under 4 ℃, be respectively the beta-propiolactone solution-treated SARS virus liquid of 1: 4000,1: 6000,1: 8000 (volume ratio) dilution with working concentration, obtain SARS virus and calculate that inactivation time was respectively 2.9 hours, 7.2 hours and 11.6 hours, the results are shown in Table 2.At least 2 times of times of prolongation are inactivation time first on this basis.The deactivation kinetic curve is referring to Fig. 2.
The table 2 different concns beta-propiolactone deactivation of SARS virus time
Calculate inactivation time before the deactivation
Beta-propiolactone concentration slope
CCID50/ml????????????????(hr)
1∶4000????????????7.2???????-2.4????????????2.9
1∶6000????????????7.2???????-1.025??????????7.2
1∶8000????????????7.2???????-0.63???????????11.6
In the present invention can also be in the cell factory of scale preparation SARS virus the original position deactivation of SARS virus.
With the inactivator for preparing, promptly through the formalin solution of 1: 100 (volume ratio) dilution, the equivalent adding fills in the cell factory (available from Denmark NUNC company) for the treatment of deactivation of SARS virus mixing, under agitation, gather in the crops after 2.9～12.5 hours through 37 ℃ of original position deactivations.
Perhaps when adopting beta-propiolactone solution, 1: 10 dilution back is added, make that beta-propiolactone solution and gross sample volume ratio are 1: 6000～1: 8000 as inactivator.2～8 ℃ of deactivation temperature 16～24 hours.
Overtime deactivation of embodiment 3 SARS virus or secondary deactivation
1) be that inactivator is handled the inactivation of virus liquid that obtains to adopt formalin by embodiment 2 gained, with its with deactivation condition identical as described in embodiment 2 under carry out overtime deactivation with 3 times of inactivation time first.
2) be that inactivator is handled the inactivation of viruses liquid that obtains to adopt beta-propiolactone by embodiment 2 gained, carry out the secondary deactivation.Add once more with viral sample cumulative volume ratio be that the amount of 1: 4000～1: 6000 (be twice add beta-propiolactone working concentration sum) is carried out the secondary deactivation, the second deactivation condition is at 2-8 ℃ of following deactivation of SARS virus 16-24 hour, room temperature effect 2 days or 37 ℃ of water-bath effects 2 hours are with the thorough deactivation of SARS virus.
The checking of embodiment 4 SARS virus inactivating efficacies
To described in embodiment 2 or 3, finish the SARS virus liquid of inactivation of virus or viral overtime deactivation (or secondary deactivation), sampling (20～100ml) respectively, adopt 3 generations of the continuous blind passage of sensitive cells, carry out the inactivating efficacy proof test, cytopathy detection method (CPE) or direct, indirect immunofluorescence (IF) with standard, whether monitoring virus verifies its inactivating efficacy by thorough deactivation, guarantees the security of production of vaccine.
Adopt the antigenicity of reverse indirect hemagglutination method detection SARS virus deactivation front and back, the antigenic content no significant difference, the result is as shown in table 3:
Antigenicity detected result before and after the deactivation of three batches of SARS virus liquid of table 3
Antigenic content (hemagglutinative titer)
Lot number
After the preceding deactivation of deactivation
F30307-008?????????1∶224???????????????1∶192
F30308-022?????????1∶160???????????????1∶128
F30308-024?????????1∶160???????????????1∶192
The above results shows that the SARS virus through method described in the previous embodiment 1-3 of the present invention is handled still has the antigenicity that is suitable for preparing vaccine after deactivation.
The purifying of embodiment 6 deactivation of SARS virus
To carry out following operation as embodiment 3 gained inactivation of virus liquid, with purifying gained inactivation of virus liquid:
1) centrifugal clarification, promptly with 2000～4000g centrifugal force 2-8 ℃ centrifugal 10～35 minutes, suct clearly, obtain viral clear liquor;
2) ultrafiltration and concentration: viral clear liquor is carried out ultrafiltration and concentration more than 10 times with the film bag of 100-500kd (molecular weight cut-off), equal-volume dialysis 3-7 time, dialyzate usefulness 0.01M PBS (pH7.0～7.6) obtains viral ultrafiltrated;
3) column chromatography: viral ultrafiltrated is carried out chromatography with Sepharose four fast flow, collect the first percolation peak and be viral purification liquid.Elutriant 0.01M PBS.
Perhaps, will carry out following operation as embodiment 3 gained inactivation of virus liquid, with purifying gained inactivation of virus liquid:
1) inactivation of virus liquid is carried out centrifugal clarification, concrete with 2000～4000g centrifugal force 2-8 ℃ centrifugal 10～35 minutes, suct clearly, be viral clear liquor;
2) ultrafiltration and concentration: viral clear liquor is carried out ultrafiltration and concentration more than 10 times with the film bag of 100-500kd (molecular weight cut-off), equal-volume dialysis 3-7 time, dialyzate obtains viral ultrafiltrated with 0.01M PBS (pH7.0～7.6);
3) to step 2) purified inactivation of viruses liquid in add the final concentration Benzonase of 10-100 unit (Merck ﹠ Co., Inc.), 1-10mM Mg
2+Room temperature treatment is more than 4 hours, the RNA of Vero cell residue DNA and system in the digestion system; Vero cell residue DNA in the digestion system;
4) ultrafiltration once more;
5) column chromatography: viral ultrafiltrated is carried out chromatography with Sepharose four fast flow, and elutriant 0.01M PBS collects the first percolation peak and is viral consummate liquid.
Perhaps, will carry out following operation as embodiment 3 gained inactivation of virus liquid, with purifying gained inactivation of virus liquid:
1) inactivation of virus liquid is carried out centrifugal clarification, concrete with 2000～4000g centrifugal force 2-8 ℃ centrifugal 10～35 minutes, suct clearly, be viral clear liquor;
2) ultrafiltration and concentration: viral clear liquor is carried out ultrafiltration and concentration more than 10 times with the film bag of 100-500kd (molecular weight cut-off), equal-volume dialysis 3-7 time, dialyzate obtains viral ultrafiltrated with 0.01M PBS (pH7.0～7.6);
3) column chromatography: viral ultrafiltrated is carried out chromatography with Sepharose four fast flow, and elutriant 0.01M PBS collects the first percolation peak;
4) add the final concentration Benzonase of 10-100 unit (Merck ﹠ Co., Inc.), 1-10mM Mg in the purified inactivation of viruses liquid of in step 3), collecting
2+Room temperature treatment is more than 4 hours, the RNA of Vero cell residue DNA and system in the digestion system;
5) ultrafiltration once more obtains viral consummate liquid.
The preparation of embodiment 7 inactivated virus vaccine
Will through the inactivation of virus liquid of the described method deactivation of embodiment 1-3 according to embodiment 6 described method purifying after, gained viral purification liquid is further passed through following processing:
1) the consummate liquid of virus was shone samples (volume is not limit) 60 minutes with the cobalt 60 that is selected from 0.2 μ m filter or 4-10 kilogray (kGy) dosage, degerming obtains vaccinogen liquid;
2) vaccinogen liquid is diluted to total protein 10-50 mcg/ml or 10-100SU/ milliliter SARS antigen (SARS antigen unit represents that with SU 1SU is meant and can makes mouse produce 64 antigen amounts that neutralizing antibody unit is required) with water for injection, is packed as inactivated vaccine;
3) choose wantonly, employing contains the aluminium diluent of adjuvant aluminium hydroxide: aluminium hydroxide concentration is 0.7-1.2mol/L, 0.01MPBS, pH6.8-7.2, vaccinogen liquid is diluted to total protein 10-50 mcg/ml or 10-100SU/ milliliter SARS antigen (SARS antigen unit represents that with SU 1SU is meant and can makes mouse produce 64 antigen amounts that neutralizing antibody unit is required), and aluminium hydroxide content is 0.35-0.62mol/L, pH6.8-7.2 is packed as inactivated vaccine;
4) or optional, with the influenza vaccines stoste (total protein 100-300 mcg/ml, the H that contain influenza hemagglutinin
1N
1, H
3N
2, the Type B influenza virus hemagglutinin is respectively greater than 12 micrograms) the above-mentioned SARS vaccinogen liquid of dilution, obtaining with the influenza hemagglutinin is the SARS vaccine of adjuvant.
The safety evaluation of embodiment 8 SARS vaccines, immunogenicity and efficiency assay result
Will be as the prepared inactivated virus vaccine of embodiment 7, inoculate mouse by the intramuscular inoculation rhesus monkey or according to 20～40ug/1.0ml dosage by abdominal injection according to 40～100ug/1.0ml dosage, carry out security, immunogenicity and the efficiency assay of vaccine.The animal of vaccination group as a result and not vaccination group (inoculation sorbent material), all there is not clinical symptom through observing, its ight soil, movement all do not detect SARS virus, and histoorgan does not have pathology yet and changes, the animal test results preliminary identification security of inactivated vaccine.
Blood sampling in 10,15,30 days after the vaccine inoculation; adopt conventional EIA method to detect SARS virus IgG antibody and conventional cell neutralization test method detection protectiveness neutralizing antibody; its total antibody of IgG all sun commentaries on classics in 10 days as a result shows that this vaccine has good immunogenicity, and the result sees table 4 for details.
With in 10,15,30 days simian immunodeficiency serum and the different SARS strains and after carry out the cell neutralization test, the result confirms that its immune serum all has good neutralizing effect to different SARS strains, on average can reach 1 with antibody titer in it: 16-1: 32, the validity that is vaccine is able to tentative confirmation, and the result sees table 5 for details.
10,15,30 days total antibody test results of IgG after the table 4 SARS inactivated vaccine immunization
| Monkey number | Antibody titer after the immunization (detection of EIA method) |
| 10 days 15 days 30 days | |
| ????1 ????2 ????3 ????4 ????5 | ?????+??????????+???????????+ ?????+??????????+???????????+ ?????+??????????+???????????+ ?????+??????????+???????????+ ?????+??????????+???????????+ |
10,15,30 days neutralizing antibody detected results after the table 5 SARS inactivated vaccine immunization
| Monkey number | Immunity back different time NAT (cell neutralization test) |
| 10 days 15 days 30 days | |
| ????1 ????2 ????3 ????4 ????5 | ????1∶16????????1∶16-32?????????1∶32 ????1∶16????????1∶16????????????1∶16-32 ????1∶16????????1∶16????????????1∶32 ????1∶16????????1∶16????????????1∶32 ????1∶16????????1∶16????????????1∶32 |
Animal trial test result confirms the inactivated vaccine that this present invention is prepared substantially, not only has good security and immunogenicity, and neutralization test result has further confirmed the validity of this vaccine.
Claims (13)
1. the ablation method of a SARS virus, it comprises the steps:
1) at 37 ℃ with long-pending than being 1 with pending population of samples: 1000-1: 4000 formalin solution is that the inactivator concentration of treatment is 1: the SARS virus sample liquid of 128-192 (hemagglutinative titer), 2.9-12.5 hour; Perhaps
2) at 2-8 ℃ with long-pending than being 1 with pending population of samples: 6000-1: 8000 beta-propiolactone concentration of treatment is 1: the SARS virus sample liquid of 128-192 (hemagglutinative titer), 16-24 hour;
3) choose wantonly, also comprise the step of secondary deactivation or overtime deactivation.
2. the described ablation method of claim 1, wherein,
1) under 37 ℃, uses with pending population of samples long-pendingly, obtain the SARS virus deactivation liquid of complete inactivation than the formalin solution processing 2.9 hours, 6.0 hours and 12.5 hours that is respectively 1: 1000,1: 2000,1: 4000; Perhaps
2) at 2-8 ℃ with long-pending than the 16-24 hour SARS virus sample of beta-propiolactone solution-treated SARS virus sample that is respectively 1: 6000,1: 8000 with pending population of samples.
3. when the described ablation method of claim 1, wherein said overtime deactivation are meant and are inactivator with the formalin solution, with the gained deactivation of SARS virus through 3 times overtime deactivation of inactivation time first; When described secondary deactivation is meant and is inactivator with the beta-propiolactone, adding and viral sample cumulative volume ratio are that the amount of 1: 4000～1: 6000 (be twice add beta-propiolactone working concentration sum) is carried out the secondary deactivation, the second deactivation condition is at 2-8 ℃ of following deactivation of SARS virus 16-24 hour, room temperature effect 2 days or 37 ℃ of water-bath effects 2 hours.
4. SARS virus deactivation liquid according to the preparation of the described method of claim 1.
5. the described SARS virus deactivation of purifying claim 3 liquid is with the method for the deactivation of SARS virus of preparation purifying, and it comprises the following scheme that is selected from:
A) purification scheme one:
1) inactivation of virus liquid is carried out centrifugal clarification, concrete with 2000～4000g centrifugal force 2-8 ℃ centrifugal 10～35 minutes, suct clearly, be viral clear liquor;
2) ultrafiltration and concentration: viral clear liquor is carried out ultrafiltration and concentration more than 10 times with the film bag of 100-500kd (molecular weight cut-off), equal-volume dialysis 3-7 time, dialyzate obtains viral ultrafiltrated with 0.01M PBS (pH7.0～7.6); And
3) column chromatography: viral ultrafiltrated is carried out chromatography with Sepharose four fast flow, and elutriant 0.01M PBS collects the first percolation peak and is viral consummate liquid;
B) purification scheme two
1) inactivation of virus liquid is carried out centrifugal clarification, concrete with 2000～4000g centrifugal force 2-8 ℃ centrifugal 10～35 minutes, suct clearly, be viral clear liquor;
2) ultrafiltration and concentration: viral clear liquor is carried out ultrafiltration and concentration more than 10 times with the film bag of 100-500kd (molecular weight cut-off), equal-volume dialysis 3-7 time, dialyzate obtains viral ultrafiltrated with 0.01M PBS (pH7.0～7.6);
3) to step 2) to add final concentration in the purified inactivation of viruses liquid of gained be the nuclease of 10-100 unit, is preferably Benzonase; Vero cell residue DNA in the digestion system;
4) ultrafiltration once more;
5) column chromatography: viral ultrafiltrated is carried out chromatography with Sepharose four fast flow, and elutriant 0.01M PBS collects the first percolation peak and is viral consummate liquid;
C) purification scheme three
1) inactivation of virus liquid is carried out centrifugal clarification, concrete with 2000～4000g centrifugal force 2-8 ℃ centrifugal 10～35 minutes, suct clearly, be viral clear liquor;
2) ultrafiltration and concentration: viral clear liquor is carried out ultrafiltration and concentration more than 10 times with the film bag of 100-500kd (molecular weight cut-off), equal-volume dialysis 3-7 time, dialyzate obtains viral ultrafiltrated with 0.01M PBS (pH7.0～7.6);
3) column chromatography: viral ultrafiltrated is carried out chromatography with Sepharose four fast flow, and elutriant 0.01M PBS collects the first percolation peak;
4) adding final concentration in the purified inactivation of virus liquid of collecting in step 3) is the nuclease of 10-100 unit, is preferably Benzonase; Vero cell residue DNA in the digestion system;
5) ultrafiltration once more obtains viral consummate liquid.
6. consummate liquid of purified deactivation of SARS virus according to claim 5 method gained.
7. deactivation of SARS virus vaccine wherein contains the deactivation of SARS virus of immune significant quantity, and pharmaceutically acceptable carrier, and is optional, also contains the adjuvant of appropriate amount.
8. the described deactivation of SARS virus vaccine of claim 7, wherein containing at least a preserving number that is selected from is CGMCC 0962,0963,0964,0965 and 0966 the SARS virus through deactivation.
9. the described deactivation of SARS virus vaccine of claim 8, the SARS virus of wherein said deactivation is according to claim 3 and 5 described methods preparations.
10. the described deactivation of SARS virus vaccine of claim 7, wherein said adjuvant is selected from Al (OH)
3And influenza hemagglutinin.
11. a method for preparing the described deactivation of SARS virus vaccine of claim 7 comprises
1) with the method degerming that is selected from filtration sterilization or irradiation sterilization of the consummate liquid of the described virus of claim 6, obtains vaccinogen liquid;
2) vaccinogen liquid with claim 6 is diluted to total protein 10-50 mcg/ml or 10-100SU/ milliliter SARS antigen, is packed as inactivated vaccine.
12. the described method of claim 11, wherein 0.2 μ m filter is adopted in filtration sterilization described in the step 1), and irradiation sterilization adopts the cobalt 60 of 4-10 kilogray (kGy) dosage to shine samples 60 minutes.
13. the described method of claim 11, step 2 wherein) diluent that adopts is selected from: water for injection, containing aluminium hydroxide concentration is 0.7-1.2mol/L, 0.01MPBS, the aluminium hydroxide diluent of pH 6.8-7.2, with the influenza vaccines stoste that contains influenza hemagglutinin, total protein 100-300 mcg/ml wherein, H
1N1, H
3N
2, the Type B influenza virus hemagglutinin is respectively greater than 12 micrograms.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200310114341 CN1616654B (en) | 2003-11-12 | 2003-11-12 | Inactivating and purifying method for SARS virus and method for preparing said inactivated virus vaccine and said vaccine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200310114341 CN1616654B (en) | 2003-11-12 | 2003-11-12 | Inactivating and purifying method for SARS virus and method for preparing said inactivated virus vaccine and said vaccine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1616654A true CN1616654A (en) | 2005-05-18 |
| CN1616654B CN1616654B (en) | 2010-09-15 |
Family
ID=34760176
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200310114341 Expired - Lifetime CN1616654B (en) | 2003-11-12 | 2003-11-12 | Inactivating and purifying method for SARS virus and method for preparing said inactivated virus vaccine and said vaccine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1616654B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102133398A (en) * | 2010-09-15 | 2011-07-27 | 武汉中博生物股份有限公司 | Method for industrially producing animal influenza vaccine by using bioreactor |
| CN111569058A (en) * | 2020-06-18 | 2020-08-25 | 武汉生物制品研究所有限责任公司 | SARS-CoV-2 inactivated vaccine and its preparation method |
| CN111575249A (en) * | 2020-06-12 | 2020-08-25 | 北京生物制品研究所有限责任公司 | Purification method of novel coronavirus Vero cell inactivated vaccine virus liquid |
| CN112546213A (en) * | 2020-12-31 | 2021-03-26 | 中国医学科学院医学生物学研究所 | Method for preparing novel coronavirus vaccine and evaluation method aiming at effectiveness of novel coronavirus vaccine |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021235923A1 (en) * | 2020-05-18 | 2021-11-25 | Rse On Ecr "Research Institute For Biological Safety Problems" Of Cs Mes Rk | Method of obtaining of the inactivated vaccine for covid-19 prophylaxis |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1569228A (en) * | 2003-07-17 | 2005-01-26 | 北京华特森基因科技有限公司 | SARS vaccine and its preparation method and application |
-
2003
- 2003-11-12 CN CN 200310114341 patent/CN1616654B/en not_active Expired - Lifetime
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102133398A (en) * | 2010-09-15 | 2011-07-27 | 武汉中博生物股份有限公司 | Method for industrially producing animal influenza vaccine by using bioreactor |
| CN111575249A (en) * | 2020-06-12 | 2020-08-25 | 北京生物制品研究所有限责任公司 | Purification method of novel coronavirus Vero cell inactivated vaccine virus liquid |
| CN111575249B (en) * | 2020-06-12 | 2021-06-18 | 北京生物制品研究所有限责任公司 | Purification method of novel coronavirus Vero cell inactivated vaccine virus liquid |
| CN111569058A (en) * | 2020-06-18 | 2020-08-25 | 武汉生物制品研究所有限责任公司 | SARS-CoV-2 inactivated vaccine and its preparation method |
| CN112546213A (en) * | 2020-12-31 | 2021-03-26 | 中国医学科学院医学生物学研究所 | Method for preparing novel coronavirus vaccine and evaluation method aiming at effectiveness of novel coronavirus vaccine |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1616654B (en) | 2010-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Andre | Overview of a 5-year clinical experience with a yeast-derived hepatitis B vaccine | |
| EP0339667B1 (en) | Hepatitis A,B,-combined adjuvanted vaccine | |
| CN102154325B (en) | Vaccine against human papillomavirus (HPV) as well as preparation method and application thereof | |
| CN104099301B (en) | Coxsackie virus A16 type virus strain, application, vaccine and preparation method thereof | |
| CN1579553A (en) | Method for preparing II-type pig's ring-virus nucleic vaccine and the use thereof | |
| CN110711247A (en) | Rabies vaccine composition containing BCG-CpG-DNA adjuvant | |
| CN102198270B (en) | Preparation method of aluminum-containing adjuvant hepatitis B vaccine | |
| CN108117583B (en) | Immunopotentiator and application thereof | |
| CN101020053B (en) | Preparation process of inactivated rotavirus vaccine | |
| NZ574776A (en) | Proccess for producing poliovirus in culture using a dextran microcarrier for use in an inactivated poliovirus, diptheria, pertussis and tetanus vaccine | |
| CN1616654A (en) | Inactivating and purifying method for SARS virus and method for preparing said inactivated virus vaccine and said vaccine | |
| JP4371343B2 (en) | Enhanced immunogen for inactivated vaccine against Japanese encephalitis virus group infection and method for producing the same | |
| CN106075423B (en) | Combined vaccine for preventing hand-foot-and-mouth disease | |
| CN109432413B (en) | A kind of russian spring-summer encephalitis virus inactivated vaccine and preparation method thereof | |
| CN1843507B (en) | Mumps virus ingredient vaccine for human, and its preparation method and uses | |
| CN1250284C (en) | Hepatitis A inactivated vaccine | |
| CN112717128B (en) | Combined vaccine for preventing hand-foot-mouth disease and preparation method and application thereof | |
| CN1990041A (en) | Kidney syndrome hemorrhagic fever Vero cell bivalent purified vaccine and industrialized producing process thereof | |
| CN102174477B (en) | Hepatitis A virus strain SH and diploid cell adaptation method thereof | |
| CN1911444A (en) | Typhoid, paratyphoid ectoblast protein vaccine | |
| CN1429908A (en) | Gene modification sequence of gene recombination hepatitis virus surface antigen and its product | |
| CN1443844A (en) | Hepatitis A virus strain, method for preparing hepatitis A inactivated vaccine and obtained vaccine | |
| CN1775287A (en) | SARS influenza bivalent combined vaccine and its preparing process | |
| CN1305527C (en) | Vaccine for treating hepatitis B, and its prepn. method | |
| CN109602899B (en) | Intradermal injection technology for enhancing virus antigen immunogenicity and application thereof in hand-foot-and-mouth disease vaccine research |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CX01 | Expiry of patent term |
Granted publication date: 20100915 |
|
| CX01 | Expiry of patent term |